Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Serina Therapeutics, Inc.SER · Entity 9581 | Director | April 01, 2024 | April 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Serina Therapeutics, Inc.
Report date April 01, 2024 · Filed April 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.83 · Expires 2034-04-01 | Direct | 157,219 |
Reported balance
After 2024-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-01 · Grant · Acquired 40,000 · Balance 157,219 F1: The stock options vest in three equal installments on April 1, 2025, April 1, 2026 and April 1, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in three equal installments on April 1, 2025, April 1, 2026 and April 1, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2024 Filed Apr 3, 2024 20:55 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001493152-24-013081 · ownership.xml · derivative · entry 1 Gross Remy · CIK 0002015973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,219 Underlying: Common Stock · 40,000 shares Expires 2034-04-01 F1 · derivative.exercise_date: The stock options vest in three equal installments on April 1, 2025, April 1, 2026 and April 1, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.